TRML (Tourmaline Bio, Inc.) Short-Term Debt to Capital

Tourmaline Bio, Inc. (TRML) brings together immunology clinical trial experts, incentivizing staff through stock options and personal accountability. Management is consistently developing treatment programs for pathologies, leveraging partner support and a sustainable balance. This price chart (separate_debt_short_eq) shows that the metric stands at 0.00. The brand is strengthening its authority by creating targeted antibodies for the therapy of severe cardiovascular inflammation.

This indicator measures the proportion of short-term liabilities within the equity structure, determining the extent to which current liquidity depends on external borrowings with maturities of up to one year. The trend of short-term borrowing relative to equity reflects the financial stability of Tourmaline Bio, Inc. (TRML) while funding the development of targeted drugs to combat autoimmune pathologies until their commercialization through government healthcare systems.